- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
CHEK2 predesign siRNASynthetic RNA
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| RI11042 | 5 OD 400 ul | 13-15 days | $ 110.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
CHEK2 predesign siRNA - Additional info | |
| Gene ID | 11200 |
| Gene Symbol | CHEK2 |
| Other Names CDS1, CHK2, LFS2, RAD53, HuCds1, PP1425, CHEK2 | |
| Format HPLC purified siRNA is supplied as a dried pellet in nmol quantities. | |
| Storage Maintain refrigerated at 2-8°C for up to one week. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
CHEK2 predesign siRNA - Related products
AP4999a: CHEK2 Antibody (N-term)
AP7407a: CHK2 Antibody (C-term)
RI11042: CHEK2 predesign siRNA
DC01419: Human CHEK2 cDNA Clone
LY10024a: CHEK2 Over-expression Lysate
BP4999a: CHEK2 Antibody (N-term) Blocking Peptide
BP7407a: CHK2 Antibody (C-term) Blocking Peptide
AT1516a: CHEK2 Antibody (monoclonal) (M01)
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene.
REFERENCES
Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk. Monsees GM, et al. Breast Cancer Res Treat, 2010 May 23. PMID 20496165. BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries. Evans DG, et al. J Med Genet, 2010 Aug. PMID 20472656. A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer. Zhang S, et al. Carcinogenesis, 2010 Jul. PMID 20462940. A Large-scale genetic association study of esophageal adenocarcinoma risk. Liu CY, et al. Carcinogenesis, 2010 Jul. PMID 20453000. A mitotic role for the DNA damage-responsive CHK2 kinase. Sato K, et al. Nat Cell Biol, 2010 May. PMID 20442702.
